Sbiomedics announced on the 19th that the technology to develop Parkinson’s disease cell therapy, th..

Sbiomedics announced on the 19th that the technology to develop Parkinson’s disease cell therapy, the company’s main pipeline, has recently been decided to register a European patent. The name of the invention is ‘Dopamine Neurocell Differentiation Induction Method from Stem Cells’, and it is a technology that differentiates middle-brain dopamine neurons from starchy stem cells such as embryonic stem cells and induced pluripotent stem cells at high rates. In addition to Korea, this patent has been registered in the United States, Japan, Australia, Canada, Russia, and India, and this time, it has been decided to register in Europe, allowing entest into 39 European countries without further examination. As a result, Parkinson’s disease cell therapy manufacturing technology has secured solid ininformectual property rights in the global market.

S Biomedics’ dopamine neuron differentiation technology is a key technology for the development of Parkinson’s disease cell therapy, and other team differentiation methods control the differentiation process by mixing proteins or low-molecular compounds, while this technology is differentiated in that it can most efficiently manufacture high-rate dopamine neurons by controlling core signals with only four low-molecular compounds.

Parkinson’s disease cell therapy applying this technology was approved for clinical trials by the Ministest of Food and Drug Safety in January 2023, and is undergoing 1/2a clinical trials on 12 Parkinson’s disease patients at Yonsei University Severance Hospital. In the case of this clinical trial, patients who had been diagnosed with Parkinson’s disease for more than 5 years and revealed resistance to or side effects to existing drugs were conducted. Sbiomedics announced the results of its first-year clinical trial after cell administration in April, which was good in safety and confirmed very good results in effectiveness indicators.

Parkinson’s disease, cautilized by the death of dopamine neurons, currently has no fundamental treatment, and a method of temporarily alleviating symptoms applying a dopamine precursor, L-DOPA, is utilized as a standard treatment. However, even if a dopamine precursor capable of creating dopamine is provided from the outside, dopamine neurons that convert it into dopamine are continuously killed in the patient’s brain, so they will eventually reach their limits. Sbiomedics has developed a fundamental method of creating and supplying dying dopamine neurons, and is producing groundbreaking results through clinical trials.

“SbioMedics’ Parkinson’s disease cell therapy is an innovative advanced biopharmaceutical that implements true regenerative medicine and is proving its value through clinical trials,” stated Kim Dong-wook, CEO of SbioMedics. “We are currently preparing a preliminary meeting with the U.S. FDA for approval of upper clinical trials to enter the global market.” With the decision to register a European patent for Parkinson’s disease cell therapy development technology, Sbiomedics further solidified its strategy to enter the global market by securing ininformectual property rights.

Reporter Lee Sang-gyu

Source link

19th announced Cell develop disease Parkinsons Sbiomedics Technology th.therapy